GSK's Arexvy maintains its RSV market dominance, looks to key label expansion as Moderna's mRNA threat looms

Even with the threat of a potential new competitor in the respiratory syncytial virus (RSV) vaccine race on the horizon, GSK and its leading Arexvy shot aren’t sweating.

Over the first quarter, the vaccine once again came out ahead of Pfizer’s rival Abrysvo with 182 million pounds ($227 million) and some two-thirds of the RSV market share, GSK reported. In other terms, more than 70 million of the addressable U.S. population of 83 million have so far received GSK’s shot.